Evidence map›Paper›PMID 42018569›Full record

ArticlePLoS pathogens2026

Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo.

Jo Hendrix, Reem Al Mubarak, Matthew J Reichlen, Samuel T Tabor, Adeline Bateman, Lisa M Massoudi, Karen Rossmassler, Firat Kaya, Matthew D Zimmerman, Holly Nielsen and 5 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Adaptive immunity shapes baseline physiology ofbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jo HendrixDivision of Pulmonary, Allergy and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United states of America.ORCID https://orcid.org/0000-0001-9029-2390
Reem Al MubarakDivision of Pulmonary, Allergy and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United states of America.
Matthew J ReichlenConsortium for Applied Microbial Metrics, Aurora, Colorado, United states of America.
Samuel T TaborDivision of Pulmonary, Allergy and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United states of America.
Adeline BatemanDivision of Pulmonary, Allergy and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United states of America.
Lisa M MassoudiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United states of America.
Karen RossmasslerRocky Mountain Regional VA Medical Center, Aurora, Colorado, United states of America.
Firat KayaCenter for Discovery and Innovation and Hackensack School of Medicine, Hackensack Meridian Health, Nutley, New Jersey, United states of America.
Matthew D ZimmermanCenter for Discovery and Innovation and Hackensack School of Medicine, Hackensack Meridian Health, Nutley, New Jersey, United states of America.
Holly NielsenDivision of Pulmonary, Allergy and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United states of America.
Elizabeth A WynnRocky Mountain Regional VA Medical Center, Aurora, Colorado, United states of America.
Martin I VoskuilConsortium for Applied Microbial Metrics, Aurora, Colorado, United states of America.
Gregory T RobertsonConsortium for Applied Microbial Metrics, Aurora, Colorado, United states of America.
Camille M MooreConsortium for Applied Microbial Metrics, Aurora, Colorado, United states of America.
Nicholas D WalterDivision of Pulmonary, Allergy and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United states of America.ORCID https://orcid.org/0000-0003-0126-1993

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-antibiotic effect (PAE) describes the delay in bacterial growth that continues after antibiotics are cleared. The physiologic basis of PAE in Mycobacterium tuberculosis (Mtb) remains poorly understood. Here, we evaluated the long-standing hypothesis that PAE reflects the time required for bacteria to recover from drug-induced physiologic damage by comparing Mtb after varying durations of treatment with the four-drug isoniazid, rifampin, pyrazinamide, ethambutol combination in vitro and in BALB/c mice using two novel molecular readouts of bacterial health. In aerobic axenic culture and in the high-dose aerosol mouse model, quantification of Mtb rRNA synthesis via the RS ratio and Mtb transcriptional profiling via SEARCH-TB revealed that longer drug exposure was associated with greater injury and adaptation during treatment, as well as slower recovery after treatment, i.e., longer PAE. Recovery followed a conserved sequence, from resumption of rRNA synthesis, to broad transcriptional reprogramming, to eventual CFU change. In mice, however, physiologic recovery was markedly slower and less complete than in vitro, indicating longer PAE in the context of immunity. Our observation that PAE in Mtb depends on the duration of drug exposure and correlates with the degree of bacterial injury support the hypothesis that nonlethal physiologic damage contributes to PAE. Our observation that PAE of the standard TB regimen is longer in mice than in vitro indicates that immunity augments PAE for Mtb. Molecular evaluation of bacterial physiology provides a new basis for probing recovery from drug exposure and understanding PAE.

Indexed as

Antitubercular AgentsMycobacterium tuberculosisTuberculosisAnimalsFemaleIsoniazidMiceMice, Inbred BALB CPyrazinamideAntitubercular AgentsIsoniazidPyrazinamide

Identifiers

PMID42018569
PMCPMC13128115

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.